{"id":54575,"date":"2023-03-07T14:03:52","date_gmt":"2023-03-07T13:03:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/"},"modified":"2023-03-07T14:03:52","modified_gmt":"2023-03-07T13:03:52","slug":"arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/","title":{"rendered":"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines &amp; Rare Disease Day, April 3, 2023<\/i>\n<\/p>\n<p>SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 28, 2023.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/5\/arcturus-logo-blueback.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/21\/arcturus-logo-blueback.jpg\"><\/a><\/p>\n<p>\nThe Company also announced it will present at the Guggenheim Healthcare Talks: Genomic Medicines &amp; Rare Disease Day on April 3, 2023, at 2:10 p.m. ET.\n<\/p>\n<p>\n<b>Arcturus Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTuesday, March 28, 2023 @ 4:30 p.m. ET\n<\/li>\n<li>\nDomestic: 1-877-407-0784\n<\/li>\n<li>\nInternational: 1-201-689-8560\n<\/li>\n<li>\nConference ID: 13735876\n<\/li>\n<li>\nWebcast: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect-us.mimecast.com%2Fs%2F0lOfCxkx8YuNW4gh8ta5D%3Fdomain%3Dviavid.webcasts.com&amp;esheet=53357330&amp;newsitemid=20230307005396&amp;lan=en-US&amp;anchor=Link&amp;index=1&amp;md5=10325ff457704b707ebab8205ae098b4\" rel=\"nofollow noopener\" shape=\"rect\">Link<\/a>\n<\/li>\n<\/ul>\n<p>\n<b>Guggenheim Healthcare Talks: Genomic Medicines &amp; Rare Disease Day (Fireside Chat)<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nMonday, April 3, 2023 (2:10 p.m. ET)\n<\/li>\n<\/ul>\n<p>\nA webcast and replay of the presentation will be available on the \u201cInvestor Relations\/Events\u201d section of the Company\u2019s website at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=53357330&amp;newsitemid=20230307005396&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;index=2&amp;md5=aa46de2e8bcc738952ba8f2a39328ab1\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/ir.arcturusrx.com\/investor-calendar<\/a>\n<\/p>\n<p>\n<b>About Arcturus Therapeutics<br \/>\n<br \/><\/b>Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u2122 mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus\u2019 diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus\u2019 technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ArcturusRx.com&amp;esheet=53357330&amp;newsitemid=20230307005396&amp;lan=en-US&amp;anchor=www.ArcturusRx.com&amp;index=3&amp;md5=b834a925ef60ddab2ef423d7b400bd40\" rel=\"nofollow noopener\" shape=\"rect\">www.ArcturusRx.com<\/a>. In addition, please connect with us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FArcturusRx&amp;esheet=53357330&amp;newsitemid=20230307005396&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=7692cd482cd8cef3d0386189ca1ef622\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farcturus-therapeutics&amp;esheet=53357330&amp;newsitemid=20230307005396&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=4cd8f28328a94f4133175ff307c854b0\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>IR and Media Contacts<\/b><br \/>Arcturus Therapeutics<br \/>\n<br \/>Neda Safarzadeh<br \/>\n<br \/>VP, Head of IR\/PR\/Marketing<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x49;&#x52;&#64;&#x61;&#x72;&#99;&#x74;&#x75;&#114;&#x75;&#x73;&#114;&#x78;&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#73;R&#64;a&#114;c&#x74;u&#x72;u&#x73;r&#x78;&#46;&#x63;o&#x6d;<\/a><\/p>\n<p>Kendall Investor Relations<br \/>\n<br \/>Carlo Tanzi, Ph.D.<br \/>\n<br \/>(617) 914-0008<br \/>\n<br \/><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DUxSgwei_MHF6Q_VeMHd_py87PYvRHu1jMGxIN2kKlRqWnT5kWNXbfnAJqvf-7n29LJyZypFQhqttbrYU_EryTbrNNtMGxSrceOqEqiq8mEU%3D&amp;esheet=53357330&amp;newsitemid=20230307005396&amp;lan=en-US&amp;anchor=ctanzi%40kendallir.com&amp;index=6&amp;md5=e7aecf1b5646f56b8d99bc3afc6d6f1f\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#x74;&#97;n&#x7a;&#x69;&#64;&#107;e&#x6e;&#x64;&#97;&#108;l&#x69;&#x72;&#46;co&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines &amp; Rare Disease Day, April 3, 2023 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54575","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines &amp; Rare Disease Day, April 3, 2023 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-07T13:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/21\/arcturus-logo-blueback.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023\",\"datePublished\":\"2023-03-07T13:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/\"},\"wordCount\":396,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005396\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/\",\"name\":\"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005396\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"datePublished\":\"2023-03-07T13:03:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005396\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230307005396\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/","og_locale":"en_US","og_type":"article","og_title":"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 - Pharma Trend","og_description":"Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines &amp; Rare Disease Day, April 3, 2023 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-07T13:03:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/21\/arcturus-logo-blueback.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023","datePublished":"2023-03-07T13:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/"},"wordCount":396,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/21\/arcturus-logo-blueback.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/","url":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/","name":"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/21\/arcturus-logo-blueback.jpg","datePublished":"2023-03-07T13:03:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/21\/arcturus-logo-blueback.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230307005396\/en\/837248\/21\/arcturus-logo-blueback.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update-on-march-28-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54575"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54575\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}